Vitruvian Partners
| Company type | Private |
|---|---|
| Industry | Private Equity |
| Founded | 2006 |
| Founders | Founding Partners: Ian Riley (Advisory Partner), Michael Risman, Toby Wyles (Retired) Mark Harford (Retired), David Nahama. |
| Headquarters | London, United Kingdom / Munich, Germany / Stockholm, Sweden / Luxembourg, Luxembourg / Madrid, Spain / Miami, United States / Mumbai, India / Shanghai, China / Singapore, Singapore / San Francisco, United States |
Key people | Joined founding team: Stephen Byrne, Ben Johnson, Jussi Wuoristo |
| Products | Leveraged buyouts and growth capital |
| Total assets | VIP I: €925 million, VIP II: £1 billion, VIP III: €2.4 billion, VIP IV: €4 billion, VIP V: €7.3 billion. |
Number of employees | >100 |
| Website | www.vitruvianpartners.com |
Vitruvian Partners is a global private equity firm, focusing on growth buyout and growth capital investments in middle-market companies.
Vitruvian invests throughout Europe, the U.S. and Asia. The firm has offices in London, Munich, Madrid, Miami, Mumbai, Stockholm, Shanghai, Singapore, San Francisco and Luxembourg.
The firm was founded in 2006 by former partners of Apax Partners, BC Partners and Bridgepoint Capital. In 2008, Vitruvian completed the fundraising for its inaugural €925 million fund, the Vitruvian Investment Partnership I ("VIP I"). In December 2013, Vitruvian announced that it had closed the fundraising of its second fund, Vitruvian Investment Partnership II (“VIP II”), at its self-imposed cap of £1 billion ($1.6 billion; €1.2billion). In June 2017, Vitruvian announced that it had closed the fundraising of its third fund, Vitruvian Investment Partnership III (“VIP III”), at the hard cap of €2.4 billion. In July 2020 Vitruvian announced the closing of Vitruvian Investment Partnership IV (“VIP IV”) at the hard cap of €4.0 billion. In September 2024 Vitruvian announced the closing of Vitruvian Investment Partnership V ("VIP V") at the hard cap of €7.3 billion.
In an annual study of the long-term performance conducted by Dow Jones/HEC Vitruvian was ranked in the Top 1% of GPs (General Partners) globally for the third year running.